Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 11/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.60 |
| ▸ | KLK7 | P49862 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | XDH | P47989 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20775957 | 0.94 | KMT2A (0.67) | MEN1KMT2ARAB9APKMKDM4E | |
| SCHEMBL20773177 | 0.89 | MAPT (0.68) | MEN1KMT2ARAB9APKMKDM4E | |
| SCHEMBL20773055 | 0.86 | MEN1 (0.67) | MEN1KMT2ARAB9APKMKDM4E | |
| SCHEMBL20772467 | 0.86 | KMT2A (0.65) | MEN1KMT2ARAB9APKMKDM4E | |
| SCHEMBL30832840 | 0.86 | KMT2A (0.65) | MEN1KMT2ARAB9APKMKDM4E | |
| SCHEMBL1152724 | 0.83 | MAPT (0.61) | MEN1KMT2AKDM4EGAAMAPT | |
| SCHEMBL30237615 | 0.83 | MAPT (0.61) | MEN1KMT2AKDM4EGAAMAPT | |
| SCHEMBL12138596 | 0.83 | KDM4E (0.69) | MEN1KMT2ARAB9AKDM4EGAA | |
| SCHEMBL14668362 | 0.82 | ALDH1A1 (0.60) | MEN1KMT2ARAB9AKDM4EGAA | |
| SCHEMBL20775326 | 0.82 | ALDH1A1 (0.60) | MEN1KMT2ARAB9AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220151991-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-19 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9809545-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2978425-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9488925-B2 | Magenta toner, developer, and image forming apparatus | RICOH COMPANY, LTD. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20160046581-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-20150253687-A1 | MAGENTA TONER, DEVELOPER, AND IMAGE FORMING APPARATUS | RICOH COMPANY, LTD. (JP) | 2015-09-10 | — | — | US | disclosed |
| US-20080302269-A1 | NANOSIZED PARTICLES OF MONOAZO LAKED PIGMENT AND NON-AQUEOUS COMPOSITIONS CONTAINING SAME | XEROX CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080302269-A1 | NANOSIZED PARTICLES OF MONOAZO LAKED PIGMENT AND NON-AQUEOUS COMPOSITIONS CONTAINING SAME | XEROX CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306189-A1 | NON-AQUEOUS COMPOSITIONS CONTAINING NANOSIZED PARTICLES OF MONOAZO LAKED PIGMENT | XEROX CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080302271-A1 | NANOSIZED PARTICLES OF MONOAZO LAKED PIGMENT | XEROX CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080302275-A1 | NANOSIZED PARTICLES OF MONOAZO LAKED PIGMENT WITH TUNABLE PROPERTIES | XEROX CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306189-A1 | NON-AQUEOUS COMPOSITIONS CONTAINING NANOSIZED PARTICLES OF MONOAZO LAKED PIGMENT | XEROX CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-20040107518-A1 | Hetero-anellated ortho-aminophenols and their use as dye components | CLARIANT FINANCE (BVI) LIMITED (BR) | 2004-06-10 | — | — | US | disclosed |
| EP-1335905-A1 | HETERO-ANELLATED ORTHO-AMINOPHENOLS AND THEIR USE AS DYE COMPONENTS | Clariant International Ltd. (CH) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002038549-A1 | HETERO-ANELLATED ORTHO-AMINOPHENOLS AND THEIR USE AS DYE COMPONENTS | CLARIANT FINANCE (BVI) LTD. (GB) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151991-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | GRB2, KRAS, HRAS | MEN1 2474/4885KMT2A 2941/4885RAB9A 348/4885 |
| US-20160046581-A1 | Factor XIa Inhibitors | F11, F12, TFPI | MEN1 1105/4885KMT2A 3115/4885RAB9A 1677/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | MEN1 2778/4885KMT2A 1169/4885RAB9A 2290/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MEN1 3209/4885KMT2A 1870/4885RAB9A 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.